The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Utilization of neoadjuvant chemotherapy in stages II and III urothelial carcinoma of the bladder.
Bin Huang
No relevant relationships to disclose
Thomas Tucker
No relevant relationships to disclose
Jason R. Bylund
No relevant relationships to disclose
John J. Rinehart
No relevant relationships to disclose
Randall G. Rowland
No relevant relationships to disclose
Stephen E. Strup
No relevant relationships to disclose
Paul L. Crispen
No relevant relationships to disclose